Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

  • Quoted phrase not found.
1.

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Enghard P, Sawitzki B, Hiepe F, Radbruch A, Burmester GR, Riemekasten G, Humrich JY.

Ann Rheum Dis. 2016 Jul;75(7):1407-15. doi: 10.1136/annrheumdis-2015-207776. Epub 2015 Aug 31.

PMID:
26324847
2.

Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.

Brayer J, Fishman M.

J Immunother. 2014 Apr;37(3):187-91. doi: 10.1097/CJI.0000000000000024.

PMID:
24598453
3.

Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.

Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC.

Cancer. 2014 May 1;120(9):1426-32. doi: 10.1002/cncr.28547. Epub 2014 Jan 28.

4.

Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.

Weiss GR, Grosh WW, Chianese-Bullock KA, Zhao Y, Liu H, Slingluff CL Jr, Marincola FM, Wang E.

Clin Cancer Res. 2011 Dec 1;17(23):7440-50. doi: 10.1158/1078-0432.CCR-11-1650. Epub 2011 Oct 5.

5.

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.

Gunturu KS, Meehan KR, Mackenzie TA, Crocenzi TS, McDermott D, Usherwood EJ, Margolin KA, Crosby NA, Atkins MB, Turk MJ, Ahonen C, Fuse S, Clark JI, Fisher JL, Noelle RJ, Ernstoff MS.

J Clin Oncol. 2010 Mar 1;28(7):1196-202. doi: 10.1200/JCO.2009.24.8153. Epub 2010 Feb 1.

6.

Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.

Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW 2nd, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B.

Clin Cancer Res. 2007 Jun 1;13(11):3312-9.

7.

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.

Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA.

Clin Cancer Res. 2006 Dec 1;12(23):7046-53.

8.

Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema.

Abraham D, McGrath KG.

Allergy Asthma Proc. 2003 Jul-Aug;24(4):291-4.

PMID:
12974198
9.

Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma.

Schmidt H, Sørensen BS, von der Maase H, Bang C, Agger R, Hokland M, Nexo E.

Melanoma Res. 2002 Dec;12(6):585-92.

PMID:
12459648
10.

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA.

J Clin Oncol. 1999 Jul;17(7):2105-16. Review.

PMID:
10561265
11.

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Whittington R, Faulds D.

Drugs. 1993 Sep;46(3):446-514. doi: 10.2165/00003495-199346030-00009. Review.

PMID:
7693434

Supplemental Content

Loading ...
Support Center